Interaction between fibrates and statins-metabolic interactions with gemfibrozil

Drug Metabolism and Drug Interactions

Volumn 19, Issue 3, 2003, Pages 161-176

  Fujino, Hideki ^a   Yamada, Iwao ^a   Shimada, Shimada ^a   Hirano, Masaru ^a   Tsunenari, Yoshihiko ^a   Kojima, Junji ^a  

^a KOWA COMPANY LTD   (Japan)

Author keywords

Cerivastatin; Fibrates; Gemfibrozil; HMG CoA reductase inhibitor; Pitavastatin

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; STATINE;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG COMPETITION; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; METABOLIC INHIBITION;

EID: 0344307424     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2003.19.3.161     Document Type: Article

References (29)

1. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y. Pharmacological profile of novel synthetic inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzme A reductase. Arzneim Forsch/Drug Res 1997; 47: 904-909.
2. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis 1999; 146: 259-270.
3. Suzuki H, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs. Arzneim Forsch/Drug Res 2001; 51: 38-45.
4. Kajinami K, Mabuchi H, Saito Y. NK-104, a novel synthetic HMG-CoA reductase inhibitor. Exp Opin Invest Drugs 2000; 9: 2653-2661.
5. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, Mabuchi H, Tushima M, Sasaki J, Ogawa N, Goto Y. A randomized, double blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002; 162: 373-379.
6. Fujino H, Yamada I, Shimada S, Yoneda M. Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin layer chromatography assay - inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase. J Chromatogr B 2001; 757: 143-150.
7. Fujino H, Yamada I, Shimada S, Yoneda M. The metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase: effects on drug-metabolizing systems in rats and humans. Arzneim Forsch/Drug Res 2002; 52: 745-753.
8. Fujino H, Saito T, Tsunenari Y, Kojima J. Interaction between several medicines and statins. Arzneim Forsch/Drug Res 2003; 53: 145-153.
9. Furberg CD, Bertram P. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205-207.
10. Lau TK, Leachman DR, Lufschanowski R. Severe rhabdomyolysis accociated with the cerivastatin-gemfibrozil combination therapy: report of a case. Tex Heart Inst J 2001; 28: 142-145.
11. Igel M, Sudhop T, Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 357-364.
12. Duell PB, Connor WE, Ilingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81: 368-369.
13. Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil conbination therapy - a case report. Angiology 2000; 51: 695-697.
14. Backman JT, Kyrklund C, Kivisto KT Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-129.
15. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340-345.
16. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72: 685-691.
17. Fujino H, Yamada I, Hirano M, Kojima J, Matsumoto H, Yoneda M. Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xenobio Metab Dispos 1999; 14: 415-424.
18. Christians U, Jacobsen W, Floren L. Metabolism and drug interactions. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in transplant patients: Are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34.
19. Baba S, Terasawa Y, Kimata H, Shinohara Y, Akira K, Hasegawa H. Application of radioluminography to off-line counting of radioactivity in high-performance liquid chromatographic elutes. J Chromatogr A 1994; 663: 35-41.
20. Kimata H, Fujino H, Koide T, Yamada Y, Tsunenari Y, Yanagawa Y. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobio Metab Dispos 1998; 13: 484-498.
21. Jemal M, Rao S, Salahudeen I, Chen BC, Kates R. Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B 1999; 736: 19-41.
22. Jemal M, Ouyang Z, Chen BC, Teitz D. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 1999; 13: 1003-1015.
23. Abe S, Ono K, Mogi M, Hayashi T. High-performance liquid chromatographic method for the determination of fenofibric acid and reduced fenofibric acid in human blood, plasma and urine. Yakugaku Zasshi 1998; 118: 447-455.
24. Ludwig E, Wolfinger H, Ebner T. Assessment of microsomal tolbutamide hydroxylation by a simple thin-layer chromatography radioactivity assay. J Chromatogr B 1998; 707: 347-350.
25. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27: 410-416.
26. Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001; 29: 1359-1361.
27. Mück W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000; 39: 99-116.
28. Weaver RJ. Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 2001; 31: 499-538.
29. Benko S, Drabant S, Grezal G, Urmos I, Csorgo M, Klebovich I. Pharmacokinetic and bioequivalence study of two gemfibrozil preparations. Arzneim Forsch/Drug Res 1997; 47: 913-916.